Skip to main content
. 2016 May 11;7(22):31800–31813. doi: 10.18632/oncotarget.9309

Figure 1. rhIL23R-CHR alleviated the symptoms and delayed disease onset in CIA rats.

Figure 1

A. Mean clinical score of rats treated with rhIL23R-CHR, CsA or vehicle; B. Maximum clinical score stood for the peak severity of an individual rat in rhIL23R-CHR, CsA or vehicle-treated group; C. Ankle thickness of the left hind paws were measured by vernier caliper; D. Ankle thickness of the right hind paws were measured by vernier caliper; E. Percent change in body weight starting days post immunization. F. Radiographic analysis of joint tissues from each group; G. H&E staining of ankle joints obtained from rhIL23R-CHR, CsA or vehicle-treated group; H. Pathology scores of cell infiltration, synovitis, cartilage erosion and bone involvement in ankle joints. Data are expressed as mean ± SD. p < 0.05; p < 0.01; p < 0.001.